Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone
针对去势抵抗性前列腺癌的 MET 抑制:利妥木单抗联合米托蒽醌和泼尼松的随机 II 期研究和生物标志物分析
期刊:Clinical Cancer Research
影响因子:10
doi:10.1158/1078-0432.CCR-12-2605
Charles J Ryan, Mark Rosenthal, Siobhan Ng, Joshi Alumkal, Joel Picus, Gwenaëlle Gravis, Karim Fizazi, Frédéric Forget, Jean-Pascal Machiels, Sandy Srinivas, Min Zhu, Rui Tang, Kelly S Oliner, Yizhou Jiang, Elwyn Loh, Sarita Dubey, Winald R Gerritsen